Table 2.

Flow cytometry immunophenotyping of circulating granulocytes in patients and controls

Surface marker
Healthy subjects
Healthy stem cell donors given G-CSF
Reactive conditions*
Myeloproliferative disorders†
No.   9   6   54   90  
LAP, median (range)   5.8 (4.6-7.0)   24.5 (11.8-32.1)   5.8 (2.9-11.2)   11.3 (6.8-41.6)  
CD157, median (range)   2.3 (1.5-3.5)   5.8 (4.2-7.6)   3.2 (1.0-5.2)   5.2 (3.2-9.4)  
CD16, median (range)
 		 178.2 (153.2-242.1)
 		 76.1 (52.7-123.9)
 		 183.3 (137.8-285.8)
 		 135.6 (54.5-219.3)
 
Surface marker
Healthy subjects
Healthy stem cell donors given G-CSF
Reactive conditions*
Myeloproliferative disorders†
No.   9   6   54   90  
LAP, median (range)   5.8 (4.6-7.0)   24.5 (11.8-32.1)   5.8 (2.9-11.2)   11.3 (6.8-41.6)  
CD157, median (range)   2.3 (1.5-3.5)   5.8 (4.2-7.6)   3.2 (1.0-5.2)   5.2 (3.2-9.4)  
CD16, median (range)
 		 178.2 (153.2-242.1)
 		 76.1 (52.7-123.9)
 		 183.3 (137.8-285.8)
 		 135.6 (54.5-219.3)
 

Immunophenotypic data are expressed as MFI ratios.

*

Twenty patients had secondary erythrocytosis, 6 had secondary leukocytosis, and 28 had secondary thrombocytosis

†

Twenty-eight patients had PV, 31 had ET, and 31 had MF

View Large